Evidence map›Paper›PMID 36204856›Full record

ArticleNeural regeneration research2023

Fingolimod protects against neurovascular unit injury in a rat model of focal cerebral ischemia/reperfusion injury.

Xiao-Yu Zhu, Ting-Ting Ma, Yang Li, Ming-Qi Zhang, Liang Zhao, Jia Liang, Lian-Qiu Min

Open access · goldAbstract read
In one paragraph

Article in Neural regeneration research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xiao-Yu ZhuDepartment of Neurology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning Province, China.
Ting-Ting MaInstitution of Life Science, Jinzhou Medical University, Jinzhou, Liaoning Province, China.
Yang LiInstitution of Life Science, Jinzhou Medical University, Jinzhou, Liaoning Province, China.
Ming-Qi ZhangInstitution of Life Science, Jinzhou Medical University, Jinzhou, Liaoning Province, China.
Liang ZhaoSchool of Pharmacy, Jinzhou Medical University, Jinzhou, Liaoning Province, China.
Jia LiangInstitution of Life Science, Jinzhou Medical University, Jinzhou, Liaoning Province, China.
Lian-Qiu MinDepartment of Neurology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning Province, China.
Jinzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent research on the underlying mechanisms of cerebral ischemia indicates that the neurovascular unit can be used as a novel subject for general surveys of neuronal damage and protein mechanisms. Fingolimod (FTY-720) is a newly developed immunosuppressant isolated from Cordyceps sinensis that exhibits a wide range of biological activities, and has recently attracted much attention for the treatment of ischemic cerebrovascular diseases. In the current research, the role of FTY-720 and its possible mechanisms were assessed from an neurovascular unit perspective using a rat cerebral ischemia model. Our results revealed that FTY-720 markedly decreased infarct volume, promoted neurological function recovery, and weakened the blood-brain barrier permeability of ischemic rats. The protective roles of FTY-720 in ischemic stroke are ascribed to a combination of sphingosin-1-phosphate receptor-1 and reduced expression of sphingosin-1-phosphate receptor-1 in microvessels and reduction of interleukin-17A protein levels. These findings indicate that FTY-720 has promise as a new therapy for neurovascular protection and functional recovery after ischemic stroke.

Indexed as

astrocyteblood-brain barrierclaudin-5FTY-720interleukin-17Aischemic strokeneural protectionneurovascular unitoccludinsphingosine-1-phosphate receptor 1

Identifiers

PMID36204856
PMCPMC9700117
OpenAlexW4296538560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.